Macrophage to make tumors more susceptible to I-O therapies
By Nuala Moran
Monday, January 9, 2017
LONDON Macrophage Pharma Ltd. has raised £9 million (US$10.9 million) in a series A to commercialize a small-molecule immuno-oncology technology originally developed by chromatin biology specialist, Chroma Therapeutics Ltd.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.